118 related articles for article (PubMed ID: 16751941)
1. [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Bouskela E
Arq Bras Cardiol; 2006 May; 86(5):366-73. PubMed ID: 16751941
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome.
Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Geloneze B; Tambascia M; Bouskela E
Atherosclerosis; 2007 Nov; 195(1):138-46. PubMed ID: 17084402
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
4. [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Bouskela E; Kraemer de Aguiar LG; Nivoit P; Bahia LR; Villela NR; Bottino DA
Bull Acad Natl Med; 2007 Mar; 191(3):475-92; discussion 492-3. PubMed ID: 18072649
[TBL] [Abstract][Full Text] [Related]
5. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
[TBL] [Abstract][Full Text] [Related]
7. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Sidhu JS; Cowan D; Kaski JC
J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
[TBL] [Abstract][Full Text] [Related]
8. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Tack CJ; Ong MK; Lutterman JA; Smits P
Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
[TBL] [Abstract][Full Text] [Related]
9. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Pistrosch F; Passauer J; Fischer S; Fuecker K; Hanefeld M; Gross P
Diabetes Care; 2004 Feb; 27(2):484-90. PubMed ID: 14747233
[TBL] [Abstract][Full Text] [Related]
10. [Effects of rosiglitazone on endothelium-dependent vasodilation in patients with Type 2 diabetes].
Wu J; Lei MX; Liu L; Huang YJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 31(4):570-4. PubMed ID: 16951521
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
Sidhu JS; Cowan D; Kaski JC
Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
Tarkun I; Cetinarslan B; Türemen E; Sahin T; Cantürk Z; Komsuoglu B
Eur J Endocrinol; 2005 Jul; 153(1):115-21. PubMed ID: 15994753
[TBL] [Abstract][Full Text] [Related]
14. [Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension].
Ling HY; Feng SD; Zhou SH; Wang BX; Liu XQ; Hu B
Sheng Li Xue Bao; 2005 Apr; 57(2):125-31. PubMed ID: 15830095
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.
Lu X; Guo X; Karathanasis SK; Zimmerman KM; Onyia JE; Peterson RG; Kassab GS
Cardiovasc Diabetol; 2010 May; 9():19. PubMed ID: 20482873
[TBL] [Abstract][Full Text] [Related]
16. Vascular insulin response is preserved in non-diabetic patients with coronary artery disease, despite endothelial dysfunction.
Ihlemann N; Rask-Madsen C; Køber L; Torp-Pedersen C
Scand Cardiovasc J; 2004 Mar; 38(1):22-7. PubMed ID: 15204243
[TBL] [Abstract][Full Text] [Related]
17. Impact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in men.
Shimabukuro M; Higa N; Masuzaki H; Sata M; Ueda S
Cardiovasc Diabetol; 2016 May; 15():77. PubMed ID: 27188597
[TBL] [Abstract][Full Text] [Related]
18. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C.
Perticone F; Ceravolo R; Candigliota M; Ventura G; Iacopino S; Sinopoli F; Mattioli PL
Diabetes; 2001 Jan; 50(1):159-65. PubMed ID: 11147782
[TBL] [Abstract][Full Text] [Related]
19. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.
Jensterle M; Sebestjen M; Janez A; Prezelj J; Kocjan T; Keber I; Pfeifer M
Eur J Endocrinol; 2008 Oct; 159(4):399-406. PubMed ID: 18653546
[TBL] [Abstract][Full Text] [Related]
20. Endothelial vasodilator function in normal-weight adults with metabolic syndrome.
Dow CA; Lincenberg GM; Greiner JJ; Stauffer BL; DeSouza CA
Appl Physiol Nutr Metab; 2016 Oct; 41(10):1013-1017. PubMed ID: 27643673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
